Cargando…

Mini Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes

In the state of insulin deficiency, the growth hormone—insulin-like growth factor-I (GH–IGF-I) axis is altered due to hepatic GH resistance, which leads to GH hypersecretion and low circulating IGF-I concentration. On the other hand, both growth hormone deficiency (GHD) and GH excess have significan...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonfig, Walter, Holl, Reinhard W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387392/
https://www.ncbi.nlm.nih.gov/pubmed/30759741
http://dx.doi.org/10.3390/ijms20030772
_version_ 1783397571598745600
author Bonfig, Walter
Holl, Reinhard W.
author_facet Bonfig, Walter
Holl, Reinhard W.
author_sort Bonfig, Walter
collection PubMed
description In the state of insulin deficiency, the growth hormone—insulin-like growth factor-I (GH–IGF-I) axis is altered due to hepatic GH resistance, which leads to GH hypersecretion and low circulating IGF-I concentration. On the other hand, both growth hormone deficiency (GHD) and GH excess have significant influence on carbohydrate metabolism. These complex interactions are challenging in diagnosing GHD in subjects with type 1 diabetes mellitus (T1DM) and in treating subjects with T1DM with GH. So far, there is only limited clinical experience in GH treatment in patients with T1DM, but recently first reports on metabolic safety and efficacy of GH treatment in subjects with T1DM have been published.
format Online
Article
Text
id pubmed-6387392
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63873922019-02-27 Mini Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes Bonfig, Walter Holl, Reinhard W. Int J Mol Sci Commentary In the state of insulin deficiency, the growth hormone—insulin-like growth factor-I (GH–IGF-I) axis is altered due to hepatic GH resistance, which leads to GH hypersecretion and low circulating IGF-I concentration. On the other hand, both growth hormone deficiency (GHD) and GH excess have significant influence on carbohydrate metabolism. These complex interactions are challenging in diagnosing GHD in subjects with type 1 diabetes mellitus (T1DM) and in treating subjects with T1DM with GH. So far, there is only limited clinical experience in GH treatment in patients with T1DM, but recently first reports on metabolic safety and efficacy of GH treatment in subjects with T1DM have been published. MDPI 2019-02-12 /pmc/articles/PMC6387392/ /pubmed/30759741 http://dx.doi.org/10.3390/ijms20030772 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Bonfig, Walter
Holl, Reinhard W.
Mini Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes
title Mini Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes
title_full Mini Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes
title_fullStr Mini Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes
title_full_unstemmed Mini Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes
title_short Mini Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes
title_sort mini review/commentary: growth hormone treatment in children with type 1 diabetes
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387392/
https://www.ncbi.nlm.nih.gov/pubmed/30759741
http://dx.doi.org/10.3390/ijms20030772
work_keys_str_mv AT bonfigwalter minireviewcommentarygrowthhormonetreatmentinchildrenwithtype1diabetes
AT hollreinhardw minireviewcommentarygrowthhormonetreatmentinchildrenwithtype1diabetes